- Home
- DINO vs BMRN Comparison
DINO vs BMRN Comparison
Compare DINO & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DINO | BMRN |
|---|---|---|
| Founded | 1947 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 12.3B |
| IPO Year | 2022 | 1999 |
Fundamental Metrics
Financial Performance| Metric | DINO | BMRN |
|---|---|---|
| Price | $106.32 | $59.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | $61.50 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 2.6M | 1.7M |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | ★ 238.46 | N/A |
| EPS | ★ 8.48 | 0.77 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $8.01 | $15.02 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | ★ $12.61 | $78.32 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $45.71 | $49.26 |
| 52 Week High | $118.39 | $70.98 |
Technical Indicators
Market Signals| Indicator | DINO | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 30.49 |
| Support Level | $82.88 | $58.03 |
| Resistance Level | $118.39 | $60.99 |
| Average True Range (ATR) | 5.10 | 1.47 |
| MACD | -1.24 | -0.72 |
| Stochastic Oscillator | 23.94 | 7.00 |
Price Performance
Historical ComparisonAbout DINO HF Sinclair Corporation
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 350 distributors and 1,700 wholesale branded sites across 30 states. It also owns and operates 4,500 miles of petroleum product pipelines and terminals principally in the southwestern United States.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.